Printer Friendly

Correction in CRPC CUA guideline.

In the recent CUA Guideline on the management of CRPC, (1) there was a missing word in the caption for Figure 1.

Published online December 14, 2015.


(1.) Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG Guideline for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9:90-6.

Fig. 1. Management of castration-resistant prostate cancer (CRPC).
PSADT: prostate-specific antigen doubling time. mCRPC: metastatic CRPC.
'Pending Health Canada approval in the chemo-naive setting.

   CRPC without       mCRPC with minimal
    metastases        or no symptoms

 Scondary hormonal       Abiraterone
                        Enzalutamide *
Screen for metastases
  based on PSADT          Docetaxel

    mCRPC with          Post docetaxel

     Docetaxel           Abiraterone

    Readium-223          Enzalutamide



1. The optimal sequence of available options remains unknown.

2. Patients who have had little or no response to hormonal
agents or who progress with minimal change in PSA or with
significant visceral metastases should be
considered for early chemotherapeutic options.

3. Radium-223 is not approved for patients with visceral metastases.

4. Whenever possible, clinical trials should remain the first choice
in patients with CRPC.
COPYRIGHT 2015 Canadian Urological Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CORRECTIONS
Publication:Canadian Urological Association Journal (CUAJ)
Article Type:Correction notice
Date:Nov 1, 2015
Previous Article:CUA Guideline: Management of ureteral calculi.
Next Article:Correction in author list.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters